SCHEMBL12126776

SCHEMBL12126776

COc1ccc2c(-c3ccccc3)cc3c4ccc(-c5ccc6c(c5)c(-c5ccccc5)cc5c7cc(OC)ccc7c(-c7ccccc7)cc65)cc4c(-c4ccccc4)cc3c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ HPGD P15428 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ PIN1 Q13526 1/20 0.53
▸ KMT2A Q03164 3/20 0.52
▸ ACACA Q13085 1/20 0.51
▸ BACE1 P56817 2/20 0.49
▸ TSHR P16473 1/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ ABCB1 P08183 2/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128798 0.90 ACACA (0.54) KDM4ESMN1; SMN2HPGDALDH1A1PIN1
SCHEMBL11367640 0.83 ACACA (0.48) KDM4ESMN1; SMN2HPGDALDH1A1PIN1
SCHEMBL12124225 0.81 CYP11B2 (0.58) KDM4ESMN1; SMN2HPGDALDH1A1ACACA
SCHEMBL12126759 0.80 ACACA (0.46) KDM4ESMN1; SMN2HPGDALDH1A1ACACA
SCHEMBL2809119 0.79 CYP1A2 (0.53) ALDH1A1KMT2ATSHRMEN1CYP3A4
SCHEMBL1615035 0.79 CYP1A2 (0.53) ALDH1A1KMT2ATSHRMEN1CYP3A4
SCHEMBL19910963 0.78 ABL1 (0.55) KDM4ESMN1; SMN2HPGDALDH1A1ACACA
SCHEMBL17536913 0.78 MAPT (0.59) KDM4ESMN1; SMN2HPGDALDH1A1KMT2A
SCHEMBL2021618 0.78 MAPT (0.59) KDM4ESMN1; SMN2HPGDALDH1A1KMT2A
SCHEMBL1615040 0.78 MAPT (0.59) KDM4ESMN1; SMN2HPGDALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580400-B2 Bichrysene compound and organic light emitting device having the compound CANON KABUSHIKI KAISHA (JP) 2013-11-12 — — US disclosed
US-8580400-B2 Bichrysene compound and organic light emitting device having the compound CANON KABUSHIKI KAISHA (JP) 2013-11-12 — — US disclosed
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-11-10 — — US disclosed
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND PPOX, CRY1, OXER1 KDM4E 3389/4885SMN1; SMN2 3222/4885HPGD 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback